POETYK PsA-1 - Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis
van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and structural damage inhibition in patients with psoriatic arthritis (PsA).
Read Article


